DE68911776D1 - Konjugierte Oxybutenolide zur Behandlung von Ulcera. - Google Patents

Konjugierte Oxybutenolide zur Behandlung von Ulcera.

Info

Publication number
DE68911776D1
DE68911776D1 DE89112692T DE68911776T DE68911776D1 DE 68911776 D1 DE68911776 D1 DE 68911776D1 DE 89112692 T DE89112692 T DE 89112692T DE 68911776 T DE68911776 T DE 68911776T DE 68911776 D1 DE68911776 D1 DE 68911776D1
Authority
DE
Germany
Prior art keywords
oxybutenolides
ulcers
conjugated
treatment
conjugated oxybutenolides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89112692T
Other languages
English (en)
Other versions
DE68911776T2 (de
Inventor
Yoshin Tamai
Masahiro Torihara
Yoichi Kido
Johji Yamahara
Masayoshi Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuraray Co Ltd
Original Assignee
Kuraray Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuraray Co Ltd filed Critical Kuraray Co Ltd
Publication of DE68911776D1 publication Critical patent/DE68911776D1/de
Application granted granted Critical
Publication of DE68911776T2 publication Critical patent/DE68911776T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE89112692T 1988-07-11 1989-07-11 Konjugierte Oxybutenolide zur Behandlung von Ulcera. Expired - Fee Related DE68911776T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63172964A JPH0222271A (ja) 1988-07-11 1988-07-11 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤

Publications (2)

Publication Number Publication Date
DE68911776D1 true DE68911776D1 (de) 1994-02-10
DE68911776T2 DE68911776T2 (de) 1994-04-14

Family

ID=15951626

Family Applications (1)

Application Number Title Priority Date Filing Date
DE89112692T Expired - Fee Related DE68911776T2 (de) 1988-07-11 1989-07-11 Konjugierte Oxybutenolide zur Behandlung von Ulcera.

Country Status (5)

Country Link
US (1) US4950818A (de)
EP (1) EP0350878B1 (de)
JP (1) JPH0222271A (de)
DE (1) DE68911776T2 (de)
ES (1) ES2061811T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134128A (en) * 1987-06-08 1992-07-28 Allergan, Inc. Anti-inflammatory furanones
US5171863A (en) * 1987-06-08 1992-12-15 Allergan, Inc. Intermediates for preparing 4-substituted 2-5(H)-furanones as anti-inflammatory agents
US5045564A (en) * 1988-12-07 1991-09-03 Allergan, Inc. Anti-inflammatory 2-furanones
JP2790335B2 (ja) * 1989-09-20 1998-08-27 株式会社クラレ 共役γ―オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤
US5112853A (en) * 1989-11-20 1992-05-12 Allergan, Inc. Anti-inflammatory furanone compounds
US5258400A (en) * 1989-11-20 1993-11-02 Allergan, Inc. Anti-inflammatory furanone compounds
US5225571A (en) * 1991-04-30 1993-07-06 Allergan, Inc. Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents
US5183906A (en) * 1991-04-30 1993-02-02 Allergan, Inc. 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
US5171864A (en) * 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5169963A (en) * 1991-08-30 1992-12-08 Allergan, Inc. Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5268387A (en) * 1992-04-24 1993-12-07 Allergan, Inc. Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss
CN111233843B (zh) * 2020-01-20 2021-07-02 中山大学 一种γ-丁烯酸内酯类衍生物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5916884A (ja) * 1982-07-19 1984-01-28 Fujisawa Pharmaceut Co Ltd 新規フラン化合物
JPS6465877A (en) * 1987-09-05 1989-03-13 Fujitsu Ltd Method of mounting optical semiconductor device

Also Published As

Publication number Publication date
US4950818A (en) 1990-08-21
EP0350878A3 (de) 1991-10-09
EP0350878A2 (de) 1990-01-17
JPH0561272B2 (de) 1993-09-06
EP0350878B1 (de) 1993-12-29
ES2061811T3 (es) 1994-12-16
DE68911776T2 (de) 1994-04-14
JPH0222271A (ja) 1990-01-25

Similar Documents

Publication Publication Date Title
DE68909219D1 (de) Behandlung von obesitas.
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE68907909D1 (de) Praeparat zur behandlung von erektionsstoerungen.
DE3584013D1 (de) Zubereitung zur behandlung von psoriasis.
FI874671A0 (fi) Anordning foer foerhindrande av laeckage i tryckledningar.
DE68907423D1 (de) Behandlung der akne.
DE3882775D1 (de) Zusammensetzung zur behandlung von parodontaler krankheit.
DE3777861D1 (de) Behandlung von gasen.
DE3869590D1 (de) Mischung zur behandlung von hypercholesterolemie.
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
DE3681642D1 (de) Benzopyran-verbindungen zur behandlung von inkontinenz.
DE3885913D1 (de) Aufbereitung von Alkoxysilanen.
DE3680881D1 (de) Behandlung von hologrammen.
DE68923219D1 (de) Behandlung von Abfällen.
NO892505L (no) Behandling av vandige dispersjoner.
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.
DE3777800D1 (de) Behandlung der wollstoffe.
DE3668116D1 (de) Zusammensetzung zur behandlung von infektionen.
ATE74537T1 (de) Behandlung von gebrauchten antimonhalidkatalysatoren.
DE68910057D1 (de) Behandlungszusammensetzungen.
DE68908413D1 (de) Behandlung von metallbrammen.
DE68918449D1 (de) Siliziumverbindungen zur behandlung von knochen.
DE3667518D1 (de) Behandlung von archivmaterial.
NO862454L (no) Fremgangsmaate for behandling av peroxydblekeavluter.
ATE91886T1 (de) Praeparat zur behandlung von erektionsstoerungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee